NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma

Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to access another revolutionary chimeric antigen receptor T-Cell (CAR T-cell) therapy through the cancer drugs fund.
Source: NHS Networks - Category: UK Health Source Type: news